Gene editing analysis company SeQure Dx said on Tuesday that it has closed a $17.5 million Series A funding round

Lyndra Therapeutics Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other

Lyndra Therapeutics Completes $60.5 Million Series C Financing

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment...

Verve Therapeutics, on the march toward the clinic with a next-gen heart drug, wants a piece of the ever-growing biotech IPO pie.

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-34

Investors back a $110M reboot effort. Source: EndPoints News Next week, Affinia Therapeutics will present four new abstracts at the...

Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia

ZP-3601 - Its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021) LYON,...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed...

Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV)

Proceeds Support Advancement of VERVE-101 toward Clinical Initiation in 2022 CAMBRIDGE, Mass. — January 19, 2021 — Verve Therapeutics, a...

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round...

A little over two years after pulling in its first Series A raise, autoimmune disease and cancer player Abcuro has some more cash to play...

LYON, France and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing...

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced

ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and other serious diseases through its ...

Amolyt and Peptidream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical....

When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with...

LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in...